Business
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8cfcff908c57e8fac40ee340a28000f3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LMwmQSCB0oLFoJsDPDVoOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8cfcff908c57e8fac40ee340a28000f3","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QTz9.rzRtz1yUWSRqXFhrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8cfcff908c57e8fac40ee340a28000f3","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Success demonstrates the power of EMMI, Terray’s proprietary AI platform integrated with its rapidly expanding 13B+ target-ligand binding database and highly automated lab","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, December 03, 2025--(BUSINESS WIRE)--Terray Therapeutics (www.terraytx.ai), a chemistry-first, AI-native biotech company, today announced the achievement of a discovery milestone in the company’s multi-target collaboration with Bristol Myers Squibb (NYSE: BMY).","length":273,"tagName":"p"},{"type":"text","content":"Terray’s EMMI platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. The company’s iterative approach integrates AI with an extensive library of quantitative, purpose-built, structure activity data to find the right molecules to solve complex problems in drug discovery.","length":352,"tagName":"p"},{"type":"text","content":""Our AI-driven platform discovers and optimizes novel molecules for the difficult-to-drug targets—the ones with no chemistry starting point," said Jacob Berlin, CEO, Terray Therapeutics. "We are excited about our success together and look forward to further progressing our discovery efforts."","length":313,"tagName":"p"},{"type":"text","content":"Terray and BMS are collaborating to accelerate small molecule drug discovery by leveraging EMMI, Terray’s integrated experimental and AI platform. This approach enables rapid, iterative experimentation combining advanced hardware, AI models, and scientific expertise, aiming to st...